Traphaco : ahead the revenue and profit curve after nine months

Traphaco's oriental medicine products hold the advantage in the market due to holding the WHO-GACP quality standard for its medicinal materials, helping to improve sales through the OTC and ETC channels in the first three quarters.

In addition, Traphaco has also been diversifying products via research and development and innovating formulas and dosage forms to ensure its products meet customer demand. For example, from its core product Boganic, Traphaco developed a series of new production lines including bottled Boganic herbal tea, Boganic Kid for Children, and Premium Boganic.
In addition to traditional medicine, which maintains its leading position in the industry, Traphaco's western medicine segment is also showing positive growth prospects. Specifically, the demand for personal healthcare products such as Antot Thymo, Sodium Chloride, and T-B is increasing in the context of the complicated COVID-19 epidemic.

Furthermore, the Traphaco eye drug group produced in a closed manufacturing line, including Quimoxi, Ofloxacin, and Tobramycin, has reported double-digit growth against the year prior. New products such as Quimodex and Samaca are highly appreciated by consumers. The growth of the eye medicine group in Vietnam is forecasted to reach 9.8 per cent per year in 2019-2024, according to a study published by Euromonitor.

According to a leader of Traphaco, the consecutive increases in past quarters is the result of its restructuring work during the past year. Accordingly, the company focused on applying modern management systems and change enterprise culture.

Traphaco selected 2020 as the year of building a corporate culture for the new period, with six core values, namely honesty, bravery, proactivity, connection, creativity, and responsibility.